A second compound selectively targeting BCL-XL in cancer is mirzotamab clezutoclax/ABBV-155 [108], an antibody-drug conjugate consisting of a BCL-XL inhibitor conjugated to a monoclonal anti-B7H3 antibody that targets the drug to cancer cells due to their selective B7H3 expression [109]. Here, CD276 is linked to cancer.